0001209191-17-047197.txt : 20170802
0001209191-17-047197.hdr.sgml : 20170802
20170802182735
ACCESSION NUMBER: 0001209191-17-047197
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170731
FILED AS OF DATE: 20170802
DATE AS OF CHANGE: 20170802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KINGSLEY ALFRED D
CENTRAL INDEX KEY: 0001229339
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12830
FILM NUMBER: 171001599
MAIL ADDRESS:
STREET 1: 150 E 57TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOTIME INC
CENTRAL INDEX KEY: 0000876343
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943127919
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
BUSINESS PHONE: 5105213390
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-07-31
0
0000876343
BIOTIME INC
BTX
0001229339
KINGSLEY ALFRED D
150 E. 57TH STREET
NEW YORK
NY
10022
1
1
0
0
See Remarks
Common Shares, no par value
2017-07-31
4
S
0
150000
2.80
D
5781555
D
Common Shares, no par value
1143346
I
By Greenbelt Corp.
Common Shares, no par value
375351
I
By Greenway Partners, LP
Option to Purchase Common Shares
3.15
2022-06-30
Common Shares
50000
50000
D
Option to Purchase Common Shares
2.72
2021-06-30
Common Shares
50000
50000
D
Option to Purchase Common Shares
3.57
2020-06-30
Common Shares
50000
50000
D
Option to Purchase Common Shares
3.11
2019-06-30
Common Shares
50000
50000
D
Option to Purchase Common Shares
4.13
2018-06-30
Common Shares
50000
50000
D
The securities were sold in a private transaction. Substantially all of the sale proceeds were invested in AgeX Therapeutics, Inc., a new subsidiary of BioTime.
Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors.
Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.
Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.
Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.
Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013.
Mr. Kingsley is Chairman of certain BioTime subsidiaries.
/s/Alfred D. Kingsley
2017-08-02